In this file:
• The hour before any patient arrives
• Where the hours actually go, ranked by time and not by glamour
• The four regulations that quietly write the job description
• What nobody puts in the posting
Of note, this is not how every clinical trial site operates. Some have specific roles doing tasks, others have study coordinators that do all of it. That’s what I did when I was a clinical trial coordinator at two small research sites.
Nani gets in at ten to seven. Not because anyone asked her to, and not because she is behind. Because the first patient is at eight, the study drug has to be pulled and reconciled before that, and the only stretch of the day that belongs to her is the one before the phone starts.
This is a Tuesday. No emergencies, nothing dramatic, one of roughly two hundred days a year that look like this. It is the honest version.
Before the door opens
The regulatory binder first, for ten minutes, because the monitor is due in three weeks and an hour spent now is four hours saved then. Nani is looking for gaps. A training record for Marcus that has not been filed. A protocol amendment approved by the IRB but not yet signed off on the delegation log. The continuing review date, which for this study is coming in November and which the IRB is required to conduct at least once a year, not whenever anyone remembers.
Then the investigational product. She counts what is in the cabinet against what the log says should be in the cabinet, and if those two numbers disagree she stops and finds out why before she does anything else. This is not fussiness. Under 21 CFR 312.62, the investigator has to keep adequate records of the disposition of the drug, including dates, quantity and use by subjects, and every one of those records is something Nani wrote.
Then the day's charts, in visit order, with the source documents she is going to need already on top.
Marcus arrives at 7:40 and asks what he can do. Nani gives him the screening log and the phone.
Where the hours actually go
Here is the ranking nobody puts in the posting, roughly by time spent across a normal week.
Documentation, first and by a distance. Not paperwork in the sense of forms. Source. Under the current Good Clinical Practice guideline, source records have to be attributable, legible, contemporaneous, original, accurate and complete, and changes have to be traceable without obscuring what was there before. Contemporaneous is the word that does the damage. It means writing it down when it happens, not at four o'clock when the day is over and you are reconstructing from memory. Every coordinator who has ever fallen behind has fallen behind on this specific thing.
Data entry and queries, second. What Nani wrote in source has to make it into the sponsor's electronic case report form, and the two have to agree. When they do not, a query comes back. The guideline puts the obligation for accuracy, completeness, legibility and timeliness of reported data on the investigator, and the investigator delegates it to the coordinator, and so the query queue is not administrative noise. It is a named regulatory duty with somebody's name on it.
Patient visits, third. This is the part people imagine the job is. Consent conversations, vitals, blood draws, dispensing and counting drug, symptom review, the diary the patient forgot to bring. It takes less of the week than documentation does, and it is the reason the rest exists.
The phone and the inbox, running underneath all of it. Scheduling, rescheduling, a patient who cannot get a ride, the lab that needs a specimen re-drawn, the pharmacy, the sponsor's project manager, the monitor confirming dates. The interruption load is the part of this job that surprises people most.
In between visits, keeping track of when to process lab samples, and how to process them according to protocol.
And when samples are ready, ensuring they’re shipped out according to the lab manual’s collection flow chart in a timely manner, with the right shipping protection provided by that study’s kits.
Regulatory and IRB work, in bursts. Amendments, continuing review, reporting to the IRB promptly when something unanticipated happens, which 21 CFR 312.66 requires the investigator to assure and which lands, in practice, on the coordinator's desk.
In the midst of the day’s work, needing to keep an eye out for when the PI or SubI is available to check medical records and adverse events to assess causation and relatedness to study drug(s) and procedures. Catching signatures in between the investigators hopping into patient visits.
Monitoring visit prep, on a cycle. Covered in the last issue. The short version: prepare so the record can be walked, not so it looks clean.
The four regulations that write the job description
Almost everything above traces to four places, and knowing them by number is one of the fastest ways to sound like you already work here.
21 CFR 312.60 puts general responsibility on the investigator: conduct the study per the signed statement, the investigational plan and the regulations, protect the rights, safety and welfare of subjects, and control the investigational drug.
21 CFR 312.62 is recordkeeping. Part (a) is drug disposition, part (b) requires adequate and accurate case histories recording all observations and other data pertinent to the investigation, and part (c) sets retention at two years past approval, or two years past discontinuation and notification if no application is filed. Note that number, because European rules run far longer and people mix them up.
21 CFR Part 50 is informed consent. Section 50.25 lists the eight required elements and six more when applicable. Section 50.27 is the one to memorize: consent is documented by a written form approved by the IRB and signed and dated by the subject at the time of consent. At the time. That single phrase is why a consent form dated a day late is not a paperwork error, and it is why the monitor checks consent before she checks anything else.
21 CFR 312.64 is reporting, and it is where the most common misunderstanding in this field lives. See below.
Behind all four sits ICH E6, Good Clinical Practice. The current version is E6(R3), adopted by ICH in January 2025, with FDA publishing its final guidance in September 2025. It is built as a principles document plus Annex 1, with Annex 2 still not final. If your training says R2, it is not wrong yet, it is just behind.
The delegation log, which is what makes your work legal
Every site keeps a delegation of authority log. Names, tasks, start dates, end dates, signed by the investigator.
New coordinators read it as a formality. It is not. FDA's guidance on investigator responsibilities says the investigator should maintain a list of the appropriately qualified people to whom significant trial-related duties have been delegated, describing the delegated tasks and identifying the training those people received, and should ensure anyone taking a task is qualified by education, training and experience. The current GCP guideline says the same thing.
What that means on a Tuesday: a task performed by someone not delegated for it on a signed, dated log is an undelegated task, no matter how competently it was performed. Marcus can run the screening log. Marcus cannot obtain consent, and he cannot evaluate an adverse event, because FDA specifically flags those as tasks that get delegated to unqualified staff and should not be.
One precision point, because plenty of sources get it wrong. The delegation log is a GCP and guidance expectation. It is not a line item in 21 CFR. The regulation it hangs off is the supervision duty in 312.60 and the commitment on the Form 1572.
Adverse events, and the timelines everybody blurs
This is the single most commonly confused thing in clinical research, so here it is separated cleanly.
The investigator's obligation. Under 21 CFR 312.64(b), the investigator must immediately report any serious adverse event to the sponsor, whether or not it is considered drug related. FDA's final guidance on investigator safety reporting, issued in December 2025, reads immediately as meaning as soon as feasible after the investigator recognizes the event is serious, and says FDA anticipates initial submission will generally not exceed one calendar day. Nonserious adverse events get recorded and reported to the sponsor on whatever timetable the protocol sets.
The investigator also provides an assessment of whether there is a reasonable possibility the drug caused the event. What the investigator does not do is decide whether the event is a suspected adverse reaction or whether it was expected. FDA is explicit that the sponsor makes that call, because the sponsor can see every event from every site and the investigator cannot.
The sponsor's obligation, which is not yours. Under 21 CFR 312.32, the sponsor notifies FDA of a serious and unexpected suspected adverse reaction no later than fifteen calendar days, and of an unexpected fatal or life-threatening one no later than seven calendar days.
Those seven and fifteen day clocks belong to the sponsor. If you say in an interview that an investigator has fifteen days to report an SAE to FDA, you have merged two different obligations, and the person across the table will notice. The investigator reports to the sponsor, immediately. The sponsor reports to FDA, on the clock.
The IRB, a third framework. 312.66 says the investigator promptly reports unanticipated problems involving risk to the IRB, without a day count. For research under the Common Rule, OHRP recommends serious adverse events reach the IRB within a week and other unanticipated problems within two. A single trial can sit under both frameworks at once, which is exactly the kind of thing a new coordinator gets wrong in month three.
Note to File: The findings inspectors actually write up are not exotic. Year after year the top categories on FDA's clinical investigator inspection reports are failure to follow the investigational plan, inadequate or inaccurate case histories, inadequate control of the investigational product, informed consent problems and safety reporting failures. That list is the coordinator's job description written from the other direction. In fiscal year 2024, FDA classified 609 clinical investigator inspections, and about eighty percent were closed with no action indicated. The system is not falling over. It is held up by people doing the five things on that list correctly, on a Tuesday, when nobody is watching.
The parts nobody puts in the posting
Three of them, and the third is the one that actually decides whether people stay.
The interruption load. The documentation obligation runs in parallel with every patient visit, every phone call and every query. Nothing pauses so you can write. Coordinators who thrive are not the ones who work fastest. They are the ones who have built a way to capture something in the ten seconds before the next thing.
The turnover, and what it costs. Researchers writing in Clinical Trials in 2023 put turnover among patient-facing clinical research professionals somewhere between thirty five and sixty one percent, and estimated the cost of replacing a coordinator at fifty to sixty thousand dollars. The professional body reported in 2025 that around eighty percent of departures happen within the first five years, with lack of training and orientation among the top reasons given. If you are hiring, that number is a warning about onboarding. If you are being hired, it is a question to ask in the interview.
The weight. You will see the same patient every three weeks for two years. You will know about their daughter's wedding and their brother's diagnosis and which arm they prefer. You are, for a lot of them, the person in the entire medical system who has the most time for them, and some of them will not finish the study. A survey of United States coordinators published in 2005 found roughly forty four percent reporting high emotional exhaustion. The same survey found seventy percent expressing job satisfaction and seventy four percent saying they would choose the profession again. That data is old and worth dating, but the shape of it matches what people in this job actually say: it is heavy and they would do it again.
There is a 2002 paper that called the study coordinator the invisible hand in clinical research, and argued the coordinator is the real frontline of human subject protection while sitting nowhere in the formal hierarchy. Twenty four years later that is still the most accurate description of the job anyone has written.
The takeaway
A clinical research coordinator spends more of the week on documentation and data than on patients, and the reason is that the record is the only part of the trial that survives. The job is written by four regulations, 21 CFR 312.60, 312.62, 312.64 and Part 50, sitting under ICH E6(R3) Good Clinical Practice, and the delegation of authority log is what makes any of your work count. The investigator reports serious adverse events to the sponsor immediately, generally within a calendar day, and the seven and fifteen day clocks people quote belong to the sponsor, not to you. It is a high interruption, high documentation, high attachment job with real turnover, and the people who stay tend to describe it as heavy and worth it in the same sentence.
Nani signs out at 5:20. Marcus is still there, filing, and she tells him to go home. He asks one more question first.
Explore more
• This is the first issue in the career track. Next in the career track: Issue 26, clinical research jobs you can get with a biology degree (https://roottorx.com/t/open-site-file)
• Following the story instead? Issue 8, what happens during a monitoring visit (https://roottorx.com/t/open-site-file)
• The whole file: roottorx.com/t/open-site-file (https://roottorx.com/t/open-site-file)
• Root to Rx: the newsletter and The Root Room, the patient-facing side of the same story, at roottorx.com (https://roottorx.com)
References
• 21 CFR 312.60 - General responsibilities of investigators (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.60)
• 21 CFR 312.62 - Investigator recordkeeping and record retention (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.62)
• 21 CFR 312.64 - Investigator reports (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.64)
• 21 CFR 312.66 - Assurance of IRB review (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.66)
• 21 CFR 312.32 - IND safety reporting, sponsor obligations (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32)
• 21 CFR 50.25 and 50.27 - Informed consent elements and documentation (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/subpart-B/section-50.27)
• 21 CFR 56.109 - IRB review of research, continuing review (eCFR) (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-56/subpart-C/section-56.109)
• FDA - E6(R3) Good Clinical Practice, guidance for industry (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp)
• FDA - Investigator Responsibilities: Protecting the Rights, Safety, and Welfare of Study Subjects (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects)
• FDA - Investigator Responsibilities: Safety Reporting for Investigational Drugs and Devices, final guidance, December 2025 (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices)
• OHRP - Guidance on Reviewing and Reporting Unanticipated Problems (https://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html)
• FDA - BIMO inspection metrics (https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/bimo-inspection-metrics)
• Freel SA, et al. "Now is the time to fix the clinical research workforce crisis." Clinical Trials. 2023;20(5):457-462. doi:10.1177/17407745231177885 (https://journals.sagepub.com/doi/10.1177/17407745231177885)
• Gwede CK, Johnsson DJ, Roberts C, Cantor AB. "Burnout in clinical research coordinators in the United States." Oncology Nursing Forum. 2005;32(6):1123-1130. doi:10.1188/05.onf.1123-1130 (https://pubmed.ncbi.nlm.nih.gov/16270108/)
• Davis AM, Hull SC, Grady C, Wilfond BS, Henderson GE. "The invisible hand in clinical research: the study coordinator's critical role in human subjects protection." Journal of Law, Medicine and Ethics. 2002;30(3):411-419. doi:10.1111/j.1748-720X.2002.tb00410.x (https://journals.sagepub.com/doi/10.1111/j.1748-720X.2002.tb00410.x)
The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. Study OLS-114 and all names are invented. Always follow your own site's SOPs, your protocol, and your PI and QA team. Characters are composites.
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States
Next in the career track: Issue 26, the roles that actually hire a science graduate with no experience.